Story perspectives

Trump Allocates $50 M to Fast-Track Psychedelic Drug Reviews

4/25/2026

Summary

Story summary

President Donald Trump signed an executive order allocating $50 million and directing the Food and Drug Administration (FDA) to fast-track reviews of psychedelic medicines.
The initiative, sparked by a conversation with podcaster Joe Rogan, signals Republican openness to soft-drug reforms.
Despite the order, psychedelics and recreational marijuana remain classified as Schedule I substances under federal law.
Sen. Tom Cotton warned that reclassifying marijuana could raise rates of psychosis and traffic fatalities.

1 of 1

Story summary

President Donald Trump signed an executive order allocating $50 million and directing the Food and Drug Administration (FDA) to fast-track reviews of psychedelic medicines.
The initiative, sparked by a conversation with podcaster Joe Rogan, signals Republican openness to soft-drug reforms.
Despite the order, psychedelics and recreational marijuana remain classified as Schedule I substances under federal law.
Sen. Tom Cotton warned that reclassifying marijuana could raise rates of psychosis and traffic fatalities.